SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal antibodies through a proprietary platform using genetically engineered cattle. The company went public via a merger with Big Rock Partners Acquisition Corp., a blank-check vehicle sponsored by Big Rock Partners LLC that completed its IPO in 2020. The de-SPAC transaction closed in October 2021, and the combined company began trading under the SABS ticker on Nasdaq. The 10-Q filed November 22, 2021 represents the company's first quarterly report as a publicly traded entity operating in the biotechnology and biopharmaceutical sector. Sign up at SpacDesk for full filings, analytics, and deal history on SABS and hundreds of other SPAC transactions.